High EGFR expression a predictor for improved survival with cetuximab plus chemotherapy
Tuesday, July 5, 2011 - 04:00
in Health & Medicine
High epidermal growth factor receptor (EGFR) expression was a good predictor of which lung cancer patients would survive longer when cetuximab (Erbitux) was added to first-line chemotherapy, according to research presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer (IASLC).